HMG-CoA reductase inhibitors (statins) in the treatment of Alzheimer's disease and why it would be ill-advise to use one that crosses the blood-brain barrier.

HMG-CoA reductase inhibitors (statins) in the treatment of Alzheimer's disease and why it would be ill-advise to use one that crosses the blood-brain barrier. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

HMG-CoA reductase inhibitors (statins) in the treatment of Alzheimer's disease and why it would be ill-advise to use one that crosses the blood-brain barrier. Abstract Text:

D L Sparks,D J Connor,P J Browne,J E Lopez,M N Sabbagh,

Increased circulating cholesterol has been long linked to an increased risk of coronary artery disease (CAD), and is now linked to an increased risk of developing Alzheimer s disease (AD). We first showed the neuropathologic link between CAD and AD as increased incidence of cerebral senile plaques in both disorders. We then showed that AD-like neuropathology occurred in the brains of cholesterol-fed rabbits; including increased -amyloid (Ab). Currently there are a number of transgenic mouse models of AD that exhibit enhanced Ab pathology if cholesterol diet is administered. Culture studies clearly show that excess cholesterol enhances beta-metabolism of amyloid precursor protein (APP) and production of -amyloidogenic peptides, and that sufficiently reducing cholesterol levels by inhibition of synthesis completely inhibits all beta-metabolism of APP. Our finding that the elevated levels of Ab in rabbits fed cholesterol diet could be cleared from the brain by resuming a control diet prompted the hypothesis that lowering cholesterol levels in the blood of AD patients may be of some clinical benefit. Pilot data suggests that therapeutically lowering circulating cholesterol may attenuate Ab production in the cholesterol-fed rabbit brain, may stabilize cognitive performance in mildly impaired AD patients, and may reduce the risk of developing AD. Accordingly, we have initiated a double-blind treatment trial evaluating Atorvastatin Na+ among 120 mild-to-moderately impaired AD subjects randomized to one of two groups receiving placebo or active drug once a day. Atorvastatin is one of a general class of HMG-CoA reductase inhibitor drugs called statins that lower cholesterol by inhibition of synthesis. We chose to use Atorvastatin in this AD Treatment Trial because it does not cross the blood-brain-barrier, and believe it would be ill-advised to use a statin that does. This position stems from the observations that excess cholesterol inhibits cholesterol synthesis and increases Ab production, that Ab kills cells in part by inhibiting cholesterol synthesis, and that statins acting at the neuronal level could further exacerbate degeneration in AD by further inhibition of necessary cholesterol synthesis.

HMG-CoA reductase inhibitors (statins) in the treatment of Alzheimer's disease and why it would be ill-advise to use one that crosses the blood-brain barrier. Publishing Authors By Initials

DL Sparks,DJ Connor,PJ Browne,JE Lopez,MN Sabbagh,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

HMG-CoA reductase inhibitors (statins) in the treatment of Alzheimer's disease and why it would be ill-advise to use one that crosses the blood-brain barrier. Journal Published:

PUBLICATION TYPE: Randomized Controlled Trial

Journal: The journal of nutrition, health & aging

VOLUME: 6

Page Numbers: 324-31

Journal Abbreviation:

ISSN: 1279-7707

DAY: 10

MONTH: 12

YEAR: 2002

HMG-CoA reductase inhibitors (statins) in the treatment of Alzheimer's disease and why it would be ill-advise to use one that crosses the blood-brain barrier. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 100893366

HMG-CoA reductase inhibitors (statins) in the treatment of Alzheimer's disease and why it would be ill-advise to use one that crosses the blood-brain barrier. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: HMG-CoA reductase inhibitors (statins) in the treatment of Alzheimer's disease and why it would be ill-advise to use one that crosses the blood-brain barrier. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for HMG-CoA reductase inhibitors (statins) in the treatment of Alzheimer's disease and why it would be ill-advise to use one that crosses the blood-brain barrier.

AFFILIATION: D. Larry Sparks, Sun Health Research Institute, 10515 W. Santa Fe Drive, Sun City, Az 85351, USA. E-mail: Larry.Sparks@SunHealth.org

Country: France

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Nutr Health Aging

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

HMG-CoA reductase inhibitors statins in the treatment of Alzheimer's disease and why it would be ill-advise to use one that crosses the blood-brain barrier Related Publications

• A method for optimising excision of the nail bed matrix.
• Certain anesthetic procedures in bronchopleuropulmonary suppurations
• Challenges to the recognition and assessment of Alzheimer's disease in American Indians of the southwestern United States.
• Commentary on "the Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics".
• Detecting Alzheimer disease before it happens: The key to prevention?
• ECT and the media.
• ECT and the media.
• Effects of cholinesterase inhibitors on rat nicotinic receptor levels in vivo and in vitro.
• HMG-CoA reductase inhibitors (statins) in the treatment of Alzheimer's disease and why it would be ill-advise to use one that crosses the blood-brain barrier.
• How to do it . . . Appear on television.
• Interactions of stroke, nonsteroidal anti-inflammatory drugs, and APOE status in dementia risk.
• Lipoma of the uterus.
• Momentum-Transport Studies in High ExB Shear Plasmas in the National Spherical Torus Experiment.
• Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial.
• Pathological correlates of cognitive decline in Alzheimer's disease.
• Peripheral clearance of amyloid beta peptide by complement C3-dependent adherence to erythrocytes.
• Postgraduate education and the doctor.
• Progressive aphasia with Lewy bodies.
• Salmonella typhi in a child with urinary tract infection and urolithiasis.
• Selective dorsal rhizotomies in the treatment of spasticity related to cerebral palsy.
• Theory of mind development in Chinese children: A meta-analysis of false-belief understanding across cultures and languages.
• [Anti-inflammatory activity of a copper complex carrying a sugar vector, and observed serum copper levels]
• [Bleedings in the early pregnancy in a total material of 48017 deliveries. Statistical evaluation]
• [Exploration of pulmonary function.]
• [Gauze plate support in thoracoplasty.]
• [Radiological & bronchographic aspects of bronchopulmonary cancer.]
• [TREATMENT OF TRACHOMA AND PANNUS WITH GANTRISIN IN THE SERVICE D'OPHTALMOLOGIE DE LA FACULT'E DE M'EDECINE DE DAMAS.]